OSTEOMIN

Composition:
Each film coated tablet contains:

Glucosamine Sulphate 2KCl	667 mg
Equiv. to Glucosamine Sulphate	500 mg
Chondroitin Sulphate	400 mg

Indications:
Provide relief to sufferers of arthritis by reducing joint inflammation and relieving associated pain. It may help increase joint mobility by restoring cartilage tissue.

Excipients: Microcrystalline cellulose, crospovidone, croscarmellose sodium, hydroxypropylcellulose, magnesium stearate, silica-colloidal anhydrous.

Dosage:
One tablet three times per day with meals.

Side Effects:
Adverse effects of glucosamine are minimal. There are reports of gastrointestinal symptoms, drowsiness, headache, and some skin rashes.

Precautions:
If you are pregnant or breast feeding, consult with your health care professional before using this product.

Contraindications:
Individuals with known hypersensitivity to any ingredients.

Pharmacological Actions:
Glucosamine sulphate is stimulating proteoglycan synthesis, inhibiting the degradation and also stimulating the regeneration of experimentally-induced cartilage damage.
Chondroitin sulphate is increased joint glycoaminoglycan concentration and a subsequent enhancement of synovial fluid viscosity. Improvement in joint structure and function by increasing endogenous synthesis of hyaluronic acid and sulphated glycoaminoglycans and reducing breakdown of joint glycoaminoglycans subsequent to decreased collagenolytic activity and inhibition of enzymes which are capable of degrading existing joint glycoaminoglycans.

Drug Interactions:
Should not take Osteomin concomitant with warfarin.

Overdosage:
No signs or symptoms of systemic toxicity of glucosamine sulphate and chondroitin sulphate have been reported.

Pregnancy and Lactation:
Not recommended taking Osteomin in pregnant women or breast-feeding women without consulting with the physician.

Pharmacokinetics:
Glucosamine sulphate as oral administration, the peak was reached at the 9th hour after administration. The elimination half-life is 58 hours. The absolute oral bioavailability is 44%. The fecal excretion in 120 hour was 11.3% of the administered dose showing that at least 88.7% of the administered dose was absorbed through the gastrointestinal tract.
Chondroitin sulphate can be absorbed orally. The bioavailability of chondroitin sulphate ranges from 15% to 24% or the orally administered dose, 10% is in the form of chondroitin sulphate and 90% in the form of depolymerized derivatives with a lower molecular weight. Chondroitin sulphate is a slow-acting drug for the treatment of osteoarthritis, characterized by a slow onset of action, with a maximal effect being attained after several months of treatment with a carryover effect that persists after cessation of therapy.

Storage:
Store below 25°C in a dry place, away from direct sunlight.

Packaging:
Ten tablets packed in a blister and 3 such blisters packed in an outer carton.

Note:
Read the instructions carefully before use.
Do not use this product after the expiry date.
Do not use this product if there are any significant changes in appearance of the tablets.
Keep out of reach of children.

Manufactured by:
MEGA LIFESCIENCES (AUSTRALIA) PTY. LTD.
(A.C.N. 076 713 392)
60, National Avenue, Pakenham,
Victoria 3810, Australia